Estrogen-Only Hormone Therapy Linked to 39% Lower Dementia Risk, Major Study Finds

A landmark study published in Neurology, the medical journal of the American Academy of Neurology, has found that women who used estrogen-only menopausal hormone therapy later in life had significantly lower odds of developing dementia and showed fewer signs of Alzheimer’s disease in their brains. The findings, based on more than 21,000 female participants, offer a fresh perspective in a long-running scientific debate about hormone therapy and brain health.

What the Study Found

Researchers from Stanford Medicine analyzed medical data from two large datasets covering 21,462 women who underwent clinical testing during their lives. Of those, nearly 3,000 women had brain autopsies performed after death, at an average age of 82, allowing scientists to directly examine brain tissue for Alzheimer’s hallmarks such as amyloid-beta plaques and tau tangles.

The results were striking:

• 39% lower odds of receiving a clinical dementia diagnosis among estrogen-only hormone therapy users
• 35% lower odds of showing Alzheimer’s-related brain changes at autopsy
• 18% of hormone therapy users showed no signs of Alzheimer’s disease at autopsy, compared with only 10% of non-users
• Biomarker tests taken while participants were alive pointed to less amyloid buildup in the brain among users
• Users also performed better on memory tests and in their ability to carry out everyday functions

Why This Study Is Different

Earlier research, most notably the Women’s Health Initiative Memory Study published in 2003, suggested that menopausal hormone therapy — particularly estrogen combined with progestin — might increase dementia risk when started at an older age. That finding sent hormone therapy usage rates plummeting from nearly 27% of women at one point to below 5% today.

This new study is the first to measure the connection between menopausal hormone therapy and reductions in Alzheimer’s-related pathological deposits in autopsied brains — the gold standard for confirming the disease.

“Our study is unique in that we looked at all the standards of Alzheimer’s diagnosis, including the gold-standard outcome: Alzheimer’s-associated hallmarks in autopsied brains,” said senior author Hadi Hosseini, PhD, associate professor of psychiatry and behavioral sciences at Stanford Medicine.

Important Caveats

The researchers are careful to stress that this study shows an association, not proof that hormone therapy prevents dementia. Several limitations deserve attention:

• The findings apply only to estrogen-only formulations, not estrogen-plus-progestin combinations
• Women in the study began therapy at an average age of 70 — much older than today’s typical patients, who usually start in their late 40s to early 50s and stop before age 60
• The study was observational, so other factors could explain the link
• Results for topical (non-oral) estrogen were not included

Who Does This Affect?

The finding carries direct implications for roughly one-third of all women of menopausal age. By age 60, more than 30% of women have had hysterectomies and no longer have a uterus — and estrogen-only therapy is specifically recommended for these women because estrogen-plus-progestin raises endometrial cancer risk in those with an intact uterus.

“MHT appears to exert a modest but meaningful and statistically significant protective effect on the risk of developing Alzheimer’s pathology,” said co-lead author Jennifer Bruno, PhD, of Stanford Medicine. “While this is by no means more powerful than such very well-known factors as age, possession of the genetic variant known as APOE4 or a history of hypertension, it’s nonetheless quite a consistent effect, spanning multiple Alzheimer’s-related outcomes.”

What Experts Say About Hormone Therapy Today

The recent medical literature increasingly suggests that menopausal hormone therapy is most beneficial when initiated during or soon after menopause. Because the women in this study were older and started therapy late, researchers believe the findings may actually underestimate the potential benefit for women who begin treatment earlier.

“For a long time, the going recommendation was ‘Don’t use MHT for memory decline,'” Bruno said. “This study flies in the face of that recommendation.”

Still, experts agree that more research is needed before any new recommendations can be made. Women considering hormone therapy should discuss the risks and benefits with their healthcare provider, taking into account their personal medical history, age, and menopausal status.

FAQ: Estrogen-Only Hormone Therapy and Dementia

Does estrogen-only hormone therapy prevent Alzheimer’s disease?

This study found a strong association between estrogen-only menopausal hormone therapy and lower odds of dementia and Alzheimer’s pathology, but it does not prove cause and effect. Randomized controlled trials are needed to confirm whether hormone therapy can actually prevent the disease.

Why does estrogen-only therapy differ from combined therapy?

Combined therapy (estrogen plus progestin) is prescribed for women with an intact uterus to protect the endometrium, while estrogen-only therapy is used by women who have had a hysterectomy. Earlier research linked the combined form to increased dementia risk, while this new study found protective associations for the estrogen-only form.

I had a hysterectomy. Should I start estrogen-only therapy to protect my brain?

Not without talking to your doctor first. Hormone therapy decisions are highly individualized and depend on your age, how long it has been since menopause, your cardiovascular risk, and your personal and family medical history. This single study is not enough to change clinical guidelines.

What are the signs of Alzheimer’s disease?

Early signs include memory loss that disrupts daily life, difficulty planning or solving problems, confusion with time or place, trouble understanding visual images, and changes in mood or personality. If you notice these symptoms, consult a healthcare professional for a proper evaluation.

What else can women do to reduce dementia risk?

Research consistently supports a brain-healthy lifestyle: regular physical activity, a balanced diet rich in vegetables and omega-3s, quality sleep, social engagement, managing blood pressure and diabetes, staying mentally active, and avoiding smoking and excessive alcohol.

This article is based on the study “Estrogen-only menopausal hormone therapy and Alzheimer’s disease outcomes” published in Neurology on August 12, 2026, and reporting by Stanford Medicine. The study was supported by the National Institute on Aging and the National Institutes of Health.